Placebo: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: April 17, 2026🚩 Report this page

Placebo

Active ingredient

GB MHRA

Drug class: -
Availability: See label
Markets covered: 1
Products on record: 1

Overview

Placebo is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	April 17, 2026

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised April 17, 2026[1]

Oral contraception. 4).

How to take

GBOfficial regulatory label· revised April 17, 2026

Sources & citations

[1]MHRA (UK) · PLGB048540187 · revised April 17, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised April 17, 2026[1]

4%). Tabulated list of adverse reactions Adverse reactions that have been identified are listed below (see table 3). Adverse reactions are listed according to the MedDRA system organ class and ranked under frequency groupings using the following convention: common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100) and rare (≥1/10,000 to <1/1,000).
4. 4 Special warning and precautions for use: - Venous thromboembolic disorders; - Arterial thromboembolic disorders; - Hypertension; - Liver tumours; - Occurrence or deterioration of conditions for which association with CHC use is not conclusive: Crohn’s disease, ulcerative colitis, epilepsy, uterine myoma, porphyria, systemic lupus erythematosus, herpes gestationis, Sydenham's chorea, haemolytic uremic syndrome, cholestatic jaundice; - Chloasma; - Acute or chronic disturbances of liver function may necessitate the discontinuation of CHC use until markers of liver function return to normal.
- Exogenous estrogens may induce or exacerbate symptoms of hereditary and acquired angioedema. The frequency of diagnosis of breast cancer is very slightly increased among CHC users. As breast cancer is rare in women under 40 years of age the excess number is small in relation to the overall risk of breast cancer.
Causation with CHC use is unknown. 4. 5). Paediatric population In a phase 3 study including 105 adolescents aged 12 to-17 years, Drovelis was well- tolerated for 6 cycles of use and no safety concerns were raised during the study. 9%).
Other adverse events were reported in ≤ 1% of the study population. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued […]

GBOfficial regulatory label· Warnings and precautions· revised April 17, 2026[1]

4. , the first day of her menstrual bleeding, and when doing so, no additional contraceptive measures are necessary. If the first tablet is taken on days 2 to 5 of the woman’s menstruation, this medicinal product will not be effective until after the first 7 consecutive days of pink active tablet-taking.
A reliable barrier method of contraception such as a condom must therefore be used additionally during these first 7 days. The possibility of pregnancy should be considered before starting Drovelis. • Changing from a CHC (combined oral contraceptive (COC), vaginal ring or transdermal patch) The woman should start with Drovelis preferably on the day after the last active tablet (the last tablet containing the active substances) of her previous COC, but at the latest on the day following the usual tablet-free or placebo tablet interval of her previous COC.
In case a vaginal ring or transdermal patch has been used the woman should start using Drovelis preferably on the day of removal, but at the latest when the next application would have been due. • Changing from a progestogen-only-method (progestogen-only pill, injection, implant) or from a progestogen-releasing intrauterine system (IUS) The woman may switch any day from the progestogen-only pill (from an implant or the IUS on the day of its removal, from an injectable when the next injection would be due) but should in all of these cases be advised to additionally use a barrier method for the first 7 consecutive days of tablet-taking.
• Following first-trimester abortion The woman may start immediately. When doing so, she needs not take additional contraceptive measures. • Following delivery or second-trimester abortion Women should be advised to start between day 21 and 28 after delivery or second- trimester abortion.
When starting later, the woman should be advised to additionally use a barrier method for the first 7 days. However, if intercourse has already occurred, pregnancy should be excluded before the actual start of CHC use or the woman has to wait for her first menstrual period.
For breast-feeding women see section

This is not medical advice. Consult a qualified healthcare professional.